门脉性肺动脉高压的诊断与治疗进展

doi:10.3969/j.issn.1672-5069.2014.02.029

Abstract

Abstract: Portopulmonary hypertension （PPHTN） is defined as the development of pulmonary arterial hypertension associated with increased pulmonary vascular resistance complicating portal hypertension, with or without advanced liver disease. The presence of PPHTN markedly increases mortality. No effective medical therapies are currently available and liver transplantation is the only accepted treatment at the time. This review stresses on the epidemiology, pathophysiology, clinical presentation, diagnosis, treatment and the prognosis of PPHTN.

Key words: Portopulmonary hypertension, Liver cirrhosis, Diagnosis, Treatment

Cai Junjun，Han Tao.. Progress in diagnosis and treatment of patients with portopulmonary hypertension[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(2): 214-217.

References

[1] Porres-Aguilar M，Altamirano JT，Torre-Delgadillo A，et al. Portopulmonary hypertension and hepatopulmonary syndrome:a clinician-oriented overview. Eur Respir Rev，2012，21（125）:223-233.
[2] Swanson KL，Wiesner RH，Nyberg SL，et al. Survival in portopulmonary hypertension:Mayo clinic experience categorized by treatment subgroups. Am J Transplant，2008，8（11）:2445-2453.
[3] McDonnell PJ，Toye PA，Hutchins GM，et al. Primary pulmonary hypertension and cirrhosis:are they related Am Rev Respir Dis，1983，127（4）:437-441.
[4] Tsiakalos A，Hatzis G，Moyssakis I，et al. Portopulmonary hypertension and serum endothelin levels in hospitalized patients with cirrhosis. Hepatobiliary Pancreat Dis Int，2011，10（4）:393-398.
[5] Chen HS，Xing SR，Xu WG，et al. Portopulmonary hypertension in cirrhotic patients:Prevalence，clinical features and risk factors. Exp Ther Med，2013，5（3）:819-824.
[6] Kawut SM，Krowka MJ，Trotter JF，et al. Clinical risk factors for portopulmonary hypertension. Hepatology，2008，48（1）:196-203.
[7] Talwalkar JA，Swanson KL，Krowka MJ，et al. Prevalence of spontaneous portosystemic shunts in patients with portopulmonary hypertension and effect on treatment. Gastroenterology，2011，141（5）:1673-1679.
[8] Krowka MJ，Miller DP，Barst RJ，et al. Portopulmonary hypertension:a report from the US-based REVEAL Registry. Chest， 2012，141（4）:906-915.
[9] Pellicelli AM，Barbaro G，Puoti C，et al. Plasma cytokines and portopulmonary hypertension in patients with cirrhosis waiting for orthotopic liver transplantation. Angiology，2010，61（8）:802-806.
[10] Roberts KE，Fallon MB，Krowka MJ，et al. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med，2009，179（9）:835-842.
[11] Hadengue A，Benhayoun MK，Lebrec D，et al. Pulmonary hypertension complicating portal hypertension:prevalence and relation to splanchnic hemodynamics. Gastroenterology，1991，100（2）:520-528.
[12] Galiè N，Hoeper MM，Humbert M，et al. Guidelines for the diagnosis and treatment of pulmonary hypertension:the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology（ESC） and the European Respiratory Society（ERS），endorsed by the International Society of Heart and Lung Transplantation （ISHLT）. Eur Heart J，2009，30（20）:2493-2537.
[13] Kim WR，Krowka MJ，Plevak DJ，et al. Accuracy of Doppler echocardiograghy in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transpl，2000，6（4）:453-458.
[14] Colle IO，Moreau R，Godinho E，et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation:a prospective study. Hepatology，2003，37（2）:401-409.
[15] Raevens S，Colle I，Reyntjens K，et al. Echocardiography for the detection of portopulmonary hypertension in liver transplant candidates:an analysis of cutoff values. Liver Transpl，2013，19（6）:602-610.
[16] Rodriguez-Roisin R，Krowka MJ， Fallon MB，et al. Pulmonary-hepatic vascular disorders（PHD）. Eur Respir J，2004，24（5）:861-880.
[17] Porres-Aguilar M，Zuckerman MJ，Figueroa-Casas JB，et al. Portopulmonary hypertension: state of the art. Ann Hepatol，2008，7（4）:321-330.
[18] Savale L，Magnier R，Le Pavec J，et al. Efficacy，safety and pharmacokinetics of bosentan in portopulmonary hypertension. Eur Respir J，2013，41（1）:96-103.
[19] Eriksson C，Gustavsson A，Kronvall T，et al. Hepatotoxicity by bosentan in a patient with portopulmonary hypertension:a case-report and review of the literature. J Gastrointestin Liver Dis，2011，20（1）:77-80.
[20] Austin MJ，McDougall NI，Wendon JA，et al. Safety and efficacy of combined use of sildenafil，bosentan and iloprost before and after liver transplantation in serever portolulmonary hypertension. Liver Transpl，2008，14（3）:287-291.
[21] Seferian A，Simonneau G. Therapies for pulmonary arterial hypertension:where are we today，where do we go tomorrow Eur Respir Rev，2013，22（129）:217-226.
[22] Findlay JY，Harrison BA，Plevak DJ，et al. Inhaled nitric oxide reduces pulmonary artery pressures in portopulmonary hypertension. Liver Transpl Surg，1999，5（5）:381-387.
[23] Krowka MJ， Plevak DJ，Findlay JY，et al. ulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl，2000，6（4）:443-450.
[24] Bozbas SS，Eyuboglu FO，Arslan NG，et al. The prevalence and the impact of portopulmonary hypertension on postoperative course in patients undergoing liver transplantation. Transplant Proc，2009，41（7）:2860-2863.
[25] Bandara M，Gordon FD，Sarwar A，et al. Successful outcomes following living donor liver transplantation for portopulmonary hypertension. Liver Transpl，2010，16（8）:983-989.
[26] Raevens S，De Pauw M，Reyntjens K，et al. Oral vasodilator therapy in patients with moderate to severe portopulmonary hypertension as a bridge to liver transplantation. Eur J Gastroenterol Hepatol，2013，25（4）:495-502.
[27] Scouras NE，Matsusaki T，Boucek CD，et al. Portopulmonary hypertension as an indication for combined heart，lung，and liver or lung and liver transplantation:literature review and case presentation. Liver Transpl，2011，17（2）:137-143.

Progress in diagnosis and treatment of patients with portopulmonary hypertension

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[3]	. Consensus on the diagnosis and therapy of hepatic fibrosis [J]. Journal of Practical Hepatology, 2019, 22(6): 793-803.
[4]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[5]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[6]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.
[7]	Cao Ce, Yu Yixing, Wang Beibei, et al.. Clinical diagnostic efficacy of enhanced magnetic resonance imaging combined with serum AFP and PIVKA-Ⅱ in the diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 896-899.
[8]	Zeng Yanni, Zhang Can, Bi Junying, et al.. Value of long-time delayed enhancement scan of MRI in the diagnosis of solitary necrotic nodule of liver [J]. Journal of Practical Hepatology, 2019, 22(6): 900-903.
[9]	Zhang Rui, Wang Jian, Chen Shiyao.. Mechanism of portal vein thrombosis in cirrhotic patients with portal hypertension and the treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 930-933.
[10]	Xing Hao, Han Jun, Yang Tian.. Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 934-937.
[11]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[12]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[13]	Wang Yueyuan, Wang Yan, Zhang Dandan. Short-term efficacy of terlipressin and octreotide combination in treatment of cirrhotic patients complicated by hepatorenal syndrome [J]. Journal of Practical Hepatology, 2019, 22(5): 684-687.
[14]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[15]	Dan Zhuyongji, Liu Zhilan, Lu Yanyan, et al. Efficacy of endoscopic sequential variceal 1igation plus sclerotherapy in treatment of patients with hepatitis B-induced liver cirrhosis complicated by esophageal gastric varices bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 692-695.